HOLLANDSK vægtkontrol i atrieflimren undersøgelse (DUTCH-WAIST)
HOLLANDSK vægtkontrol i atrieflimren undersøgelse, et multicenter, dobbeltblindt, randomiseret, parallel gruppe, placebokontrolleret forsøg
Quantify the effect of an innovative weight loss management on rhythm control.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Rationale: Weight reduction promotes reversed atrial remodeling in obese AF patients.
Objective: Quantify the effect of an innovative weight loss management on rhythm control.
Study design: Multi-center, double-blind, randomized, parallel group, placebo-controlled trial of semaglutide 2.4 mg versus placebo.
Study population: Adults with obesity and new onset persistent AF scheduled for electrical cardioversion.
Intervention: semaglutide 2.4 mg subcutaneous (s.c.) once weekly (index) compared to placebo (control), at the background of standard obesity treatment (combined lifestyle intervention) and cardiology follow-up management in both arms.
Main study parameters/endpoints: The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome. The 7 mutually exclusive outcomes hierarchically ranked from worst to best are:
-
Arrhythmic death while using anti-arrhythmic drugs (Vaughn-Williams class I or III)*
-
AF despite pulmonary vein isolation
-
AF despite current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
AF without a pulmonary vein isolation and without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
Sinus rhythm on the 12-lead ECG with the use of a pulmonary vein isolation
-
Sinus rhythm on the 12-lead ECG with current use of anti-arrhythmic drugs (Vaughn-Williams class I or III)
-
Sinus rhythm on the 12-lead ECG without the current use of anti-arrhythmic drugs (Vaughn-Williams class I or III) and without a pulmonary vein isolation
- When LTFU or death other than anti-arrhythmic death, last known rhythm will be used.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
's-Hertogenbosch, Holland
- Jeroen Bosch Ziekenhuis
-
Alkmaar, Holland
- Noordwest Ziekenhuisgroep
-
Amsterdam, Holland
- Amsterdam UMC
-
Breda, Holland
- Amphia Ziekenhuis
-
Deventer, Holland
- Deventer Ziekenhuis
-
Doetinchem, Holland
- Slingeland Ziekenhuis
-
Eindhoven, Holland
- Máxima MC
-
Emmen, Holland
- Treant Zorggroep
-
Goes, Holland
- Admiraal de Ruyter Ziekenhuis
-
Groningen, Holland
- Martini Ziekenhuis
-
Groningen, Holland
- Universitair Medisch Centrum Groningen
-
Haarlem, Holland
- Spaarne Gasthuis
-
Heerlen, Holland
- Zuyderland Medisch Centrum
-
Leeuwarden, Holland
- Frisius MC
-
Maastricht, Holland
- Maastricht UMC+
-
Roosendaal, Holland
- Bravis ziekenhuis
-
The Hague, Holland
- HagaZiekenhuis
-
The Hague, Holland
- Haaglanden Medisch Centrum
-
Utrecht, Holland
- Diakonessenhuis
-
-
Gelderland
-
Arnhem, Gelderland, Holland
- Rijnstate Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Symptomatic, first detected (at maximum 6 months prior to enrollment) persistent AF -
-
Age ≥ 18
-
Obesity, as defined as:
- BMI ≥ 30 kg/m2, or
- BMI ≥27 kg/m2 with the presence of at least one weight related comorbidity (treated or untreated, e.g. hypertension, dyslipidaemia, obstructive sleep apnea, cardiovascular disease)
-
Scheduled ECV
-
Written informed consent
Exclusion Criteria:
- Permanent AF
- Secondary AF, i.e. due to thyrotoxicosis, infection (e.g. pneumonia) or post-(cardiothoracic) surgery
- Current or previous treatment with amiodaron
- HbA1c ≥ 48 mmol/mol, <3 months prior to randomization
- History of diabetes mellitus type 1 or 2
- Prior bariatric surgery
- Use of other anti-obesity medication, <3 months prior to enrollment
- Contra-indication for, or prior use of a GLP1-receptor agonist
- History of chronic pancreatitis or acute pancreatitis <6 months
- Acute coronary syndrome <6 months
- Severe (grade III) valvular disease
- eGFR <30 mL/min/1.73m2
- Heart failure NYHA class III-IV
- Participation in another investigational drug or device study in the past 30 days (registry enrollment is allowed)
- Any condition or therapy, which would make the participant unsuitable for the study (e.g. vulnerable, non-compliance) or life-expectancy <12 months, as judged by the treating physician.
- Female who is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Intervention
Semaglutide injections + combined lifestyle intervention |
Intervention arm receives semaglutide in addition to combined lifestyle intervention |
|
Placebo komparator: Placebo
Placebo Semaglutide injections + combined lifestyle intervention |
Control arm receives placebo in addition to combined lifestyle intervention |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome
Tidsramme: At 1 year follow-up
|
The 7 mutually exclusive outcomes hierarchically ranked from worst to best are:
|
At 1 year follow-up
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Antal indlæggelser på grund af tilbagefald af AF.
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Antal ikke-planlagte hospitalsbesøg på grund af uønskede hændelser af AAD.
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Antal planlagte elektriske elkonverteringer.
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Antal ikke-planlagte elektriske elkonverteringer.
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Antal intravenøse kemiske kardioversioner (ved brug af Vaughan-Williams klasse I-lægemidler).
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Samlet antal uplanlagte cardioverioner.
Tidsramme: uge 0-52
|
uge 0-52
|
|
|
Ændring i taljeomkreds, målt i cm
Tidsramme: uge 0 og 52
|
uge 0 og 52
|
|
|
Ændring i vægt, målt i % og kg
Tidsramme: uge 0 og 52
|
uge 0 og 52
|
|
|
Ændring i BMI, målt i kg/m2
Tidsramme: uge 0 og 52
|
uge 0 og 52
|
|
|
Change in AF related symptoms measured by the modified EHRA classification between the index visit and at 12 months after the index visit.
Tidsramme: week 0 and 52
|
EHRA: European Heart Rythm Association 1= no symptoms 2a= mild symptoms; Normal dialy activity not affected, symptoms not troublesome to patient 2b= moderate symptoms; Normal daily activity not affected but patient troubled by symptoms 3= severe symptoms; Normal daily activity affected 4= disabling symptoms; Normal daily activity discontinued |
week 0 and 52
|
|
Change in quality of life measured by the EQ-5D-5L between the index visit and at 12 months after the index visit.
Tidsramme: week 0 and 52
|
Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension. LEVEL 1: indicating no problem LEVEL 2: indicating slight problems LEVEL 3: indicating moderate problems LEVEL 4: indicating severe problems LEVEL 5: indicating unable to/extreme problems |
week 0 and 52
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Ron Pisters, dr., Rijnstate Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- U1111-1275-9989
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .